Can IL4, TSLP, and ORMDL3 variants bias immune signaling toward Th2 allergic inflammation?

Genetic susceptibility plays a pivotal role in shaping atopic responses, particularly through variants that regulate epithelial barrier defense and immune polarization.

Genetic and clinical evidence

• IL4 promoter (rs2243250): The T allele of this polymorphism increases transcriptional activity, driving elevated IL-4 expression and biasing naive CD4+ T-cell differentiation toward a Th2 phenotype.
• TSLP promoter (rs3806933): This variant enhances an activator protein-1 (AP-1) binding site, significantly increasing epithelial thymic stromal lymphopoietin (TSLP) expression in bronchial cells and lowering the threshold for allergic activation.
• ORMDL3 (rs7216389): Located on the 17q21 locus, this major asthma-susceptibility variant upregulates ORMDL3 expression, which alters cellular stress responses and enhances airway inflammation.

Mechanistic pathways of granulocyte recruitment

• Sphingolipid modulation: Elevated ORMDL3 inhibits serine palmitoyltransferase (SPT), disrupting de novo sphingolipid synthesis and altering ceramide/sphingosine-1-phosphate (S1P) homeostasis to favor inflammatory pathways.
• Eosinophil activation: Th2 cytokines (IL-4, IL-5, IL-13) drive IgE class-switching and upregulate vascular adhesion molecules. ORMDL3 further facilitates eosinophil tissue recruitment and degranulation by regulating eotaxin- and IL-3-induced CD48 expression.
• Basophil signaling: Overexpressed epithelial TSLP directly primes basophils and licenses dendritic cells, generating a self-sustaining feedback loop that maintains atopic inflammation.

Bottom line

• Variants in IL4, TSLP, and ORMDL3 cooperatively bias immune signaling toward a Th2-skewed milieu, directly driving the recruitment, degranulation, and chronic activation of eosinophils and basophils in atopic diseases.